Aquestive Therapeutics, Inc. (AQST) Stock Plunged 11.57% Current-Market, Here’s Why

Aquestive Therapeutics, Inc. (AQST) stock plummeted 11.57% in the current-market trading session at the price of $1.91 after reporting topline data from the EPIPHAST trial.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


EPIPHAST Trial Topline Results

On 12th April 2022, AQST published positive topline data from its second phase EPIPHAST study evaluating AQST-109 epinephrine film. The Part 2 results completely aligned with earlier reported positive outcomes for AQST-109. Part 2 of the EPIPHAST study reaffirmed the key pharmacodynamic and pharmacokinetic measures observed during the first parts of the study. The drug candidate was well-tolerated and showed no severe adverse effects.

The EPIPHAST study is an open-label, adaptive design, randomized, crossover study in adult patients. The study compares the pharmacodynamics and pharmacokinetics of epinephrine delivered via AQST-109 film with intramuscular injection. The 12 mg dose of AQST-109 revealed quick absorption with favorable pharmacokinetics across several key metrics. In addition to these positive effects, AQST-109 showed promising pharmacodynamic effects on diastolic blood pressure, systolic blood pressure, and heart rate.

AQST Market Outlook

The patients have had finite therapeutic choices to manage anaphylaxis for decades. Most patients were not satisfied with a rescue drug. However, the AQST-109 epinephrine film supplies patients with a rescue drug in a suitable place and at the right time. The results of the drug highlight its potential to enhance the current standard of health care. AQST stock looks forward to evaluating this investigational drug in the next stage of the EPIPHAST study.

Aquestive intends to initiate the third part of the EPIPHAST study in April 2022 and anticipates completing it by Q2 of 2022. The objective of Part-3 is to keep investigating the administration of the oral film under multiple conditions for further characterization. Moreover, the company expects to conduct an end of Phase-II discussion with the U.S. FDA and start the pivotal PK study in the last six months of 2022.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles